Amneal Pharmaceuticals (AMRX) Competitors $7.66 -0.09 (-1.16%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRX vs. QGEN, ROIV, RVMD, LNTH, BBIO, TGTX, LEGN, SRPT, TLX, and ADMAShould you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Amneal Pharmaceuticals vs. Qiagen Roivant Sciences Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Qiagen (NYSE:QGEN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Does the media prefer QGEN or AMRX? In the previous week, Qiagen had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Qiagen and 7 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.45 beat Qiagen's score of 0.80 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in QGEN or AMRX? 70.0% of Qiagen shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is QGEN or AMRX more profitable? Qiagen has a net margin of 4.23% compared to Amneal Pharmaceuticals' net margin of -6.88%. Qiagen's return on equity of 13.92% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.23% 13.92% 8.40% Amneal Pharmaceuticals -6.88%-346.26%4.85% Which has higher valuation and earnings, QGEN or AMRX? Qiagen has higher earnings, but lower revenue than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B4.81$83.59M$0.36118.86Amneal Pharmaceuticals$2.79B0.85-$83.99M-$0.38-20.16 Do analysts prefer QGEN or AMRX? Qiagen presently has a consensus target price of $48.42, indicating a potential upside of 13.15%. Amneal Pharmaceuticals has a consensus target price of $10.80, indicating a potential upside of 40.99%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor QGEN or AMRX? Qiagen received 231 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.74% of users gave Amneal Pharmaceuticals an outperform vote while only 60.00% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformQiagenOutperform Votes24960.00% Underperform Votes16640.00% Amneal PharmaceuticalsOutperform Votes1894.74% Underperform Votes15.26% Which has more risk & volatility, QGEN or AMRX? Qiagen has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. SummaryQiagen beats Amneal Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRX vs. The Competition Export to ExcelMetricAmneal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.37B$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-11.267.4422.4418.48Price / Sales0.85242.70394.09103.59Price / Cash5.8065.8538.1834.62Price / Book109.436.516.774.25Net Income-$83.99M$143.21M$3.22B$248.23M7 Day Performance3.23%1.98%1.49%0.89%1 Month Performance-6.93%6.89%4.00%3.53%1 Year Performance25.16%-2.52%16.21%5.08% Amneal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRXAmneal Pharmaceuticals3.3576 of 5 stars$7.66-1.2%$10.80+41.0%+26.6%$2.37B$2.79B-11.267,600Positive NewsHigh Trading VolumeQGENQiagen3.6786 of 5 stars$42.49+1.0%$47.83+12.6%+4.0%$9.45B$1.98B118.316,030Upcoming EarningsAnalyst RevisionNews CoverageROIVRoivant Sciences2.1639 of 5 stars$11.19+1.6%$17.50+56.4%+6.6%$7.98B$122.59M-74.60860RVMDRevolution Medicines3.7684 of 5 stars$41.47+7.0%$66.67+60.8%+8.3%$7.71B$742,000.00-11.55250Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsLNTHLantheus3.98 of 5 stars$102.70+0.9%$129.43+26.0%+56.8%$7.03B$1.53B17.09700Upcoming EarningsNews CoveragePositive NewsBBIOBridgeBio Pharma4.5458 of 5 stars$35.89-1.2%$53.00+47.7%+49.7%$6.81B$221.90M-12.59400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap UpTGTXTG Therapeutics3.3352 of 5 stars$42.03+1.7%$40.67-3.2%+233.2%$6.67B$329.00M-420.26290Upcoming EarningsPositive NewsGap DownLEGNLegend Biotech2.6249 of 5 stars$34.70+1.2%$78.82+127.1%-20.1%$6.37B$627.24M-36.531,070SRPTSarepta Therapeutics4.7326 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageHigh Trading VolumeADMAADMA Biologics1.4801 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsNews CoveragePositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies QGEN Competitors ROIV Competitors RVMD Competitors LNTH Competitors BBIO Competitors TGTX Competitors LEGN Competitors SRPT Competitors TLX Competitors ADMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMRX Stock Free AMRX Stock Alerts